Investment
Features
FeesSafety
Academy
More
Pluang+

Strategy CEO confirms ongoing Bitcoin buying, holding 4% of total supply with 845,050 BTC.

Market News
18 Sep 2026
Crypto Briefing
View Source
Bullish
Strategy CEO confirms ongoing Bitcoin buying, holding 4% of total supply with 845,050 BTC.

Strategy Inc., formerly MicroStrategy, holds about 845,050 BTC, over 4% of Bitcoin's total supply, and plans to keep accumulating. CEO Phong Le emphasized the company's long-term commitment to Bitcoin, with 2026 purchases far exceeding sales. The firm raised funds through equity sales and preferred stock to finance Bitcoin buys, reinforcing its identity as a Bitcoin treasury rather than a software company. Strategy aims to remain the largest Bitcoin buyer, leveraging financial tools to manage capital costs while expanding its Bitcoin holdings.

Strategy CEO Phong Le's Bitcoin accumulation plans provide context for cryptocurrency market trends. For readers following major cryptocurrencies on Pluang as of Sep 18, 2026 21:36 WIB: 46 of 50 major cryptocurrencies rose today while 3 fell. Among notable movers, SXP dropped sharply by 46.27% to Rp37 with a typical hold time of 94 days, contrasting with UNI which gained 21.80% to Rp157,002 and had a 63% buy order activity, and THETA which rose 12.84% to Rp3,664 with 100% buy orders and a 77-day typical hold time.

More News

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy Corporation's stock is projected to rise about 8.26% to a price target of $127, down slightly from $133, reflecting confidence despite a recent price dip. The company expects a 4.42% increase in earnings per share to $1.89 and a 3.86% ris...

Analyst Insights
Bullish
1 hour ago
Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...

Market News
Bearish
2 hours ago
Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...

Company Fundamentals
Bullish
3 hours ago
Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex, a provider of human capital management solutions, will release its Q1 fiscal 2027 earnings on September 23, 2026. Analysts expect earnings per share (EPS) of $1.32, up from $1.22 last year, and revenue of about $1.63 billion, higher than las...

Company Fundamentals
Bullish
4 hours ago
Semiconductor ETFs remain strong buys amid AI-driven demand and investment growth.

Semiconductor ETFs remain strong buys amid AI-driven demand and investment growth.

iShares Semiconductor ETF and VanEck Semiconductor ETF are recommended as strong buys due to robust capital investment driven by AI infrastructure and sector demand outpacing the broader market. The AI buildout is attracting unprecedented capital int...

Market News
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App